Pay in 4 interest-free payments of $6.97 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Cardiovascular inflammation Inflammation in blood vessel walls drives atherosclerosis, the buildup of plaques that causes heart attacks and strokes
Glycemic control in people with type 2 diabetes
However, while early findings are promising, more robust clinical research is needed to confirm these effects.
Best For Patients who have plateaued on semaglutide or tirzepatide Patients with significant weight to lose (50+ pounds) Patients with fatty liver disease (MASLD/NAFLD) or metabolic syndrome Patients who want access to the most advanced mechanism currently available Patients with established GLP-1 experience and good tolerance Side Effect Comparison All three medications share a similar side effect profile driven primarily by gastrointestinal effects: Common Side Effects (All Three) Nausea most common during dose escalation, usually resolves within 2 to 4 weeks at each dose level Diarrhea reported by 15 to 25 percent of patients Vomiting reported by 8 to 15 percent Constipation reported by 6 to 12 percent Decreased appetite nearly universal and considered therapeutic Tirzepatide and retatrutide may have slightly higher rates of GI side effects than semaglutide due to the additional pathway activation
US$ 23.32
US$ 22.68
US$ 26.43
US$ 25.01
